Beijing GoBroad Boren Hospital

Beijing GoBroad Boren Hospital stands out for its state-of-the-art infrastructure, highly skilled medical staff, and extensive expertise in patient care. The hospital delivers comprehensive cancer care and specialized medical services for individuals with blood-related cancers, Parkinson’s disease, liver malignancies, and a range of hematological disorders. It is a leading healthcare institution in China dedicated to providing top-quality medical services to local and international patients. With a strong emphasis on patient-centered care, the hospital combines advanced medical technology with a compassionate approach to treatment. Internationally recognized for cellular immunotherapy in the treatment of hematologic malignancies, Beijing GoBroad Boren Hospital specializes in lymphoma, myeloma, autoimmune disorders, and leukemia. The facility spans 14,000 square meters, offering nine dedicated diagnostic and treatment zones, 19 level-100 laminar flow patient wards, high-standard surgical suites, and emergency care units. Outfitted with cutting-edge Siemens 64-slice CT scanners and 3. 0T MRI systems, the hospital is especially renowned for its success and depth of experience in managing both pediatric and adult leukemia. Leveraging advanced technologies, the hospital aims to deliver truly personalized and integrative cancer care for every patient. The hospital collaborates with distinguished specialists and scientists from leading institutions, such as the Mayo Clinic Cancer Center, who serve as key advisors. Its medical team comprises highly experienced clinicians and laboratory diagnosticians specializing in hematology, many of whom have over three decades of hands-on experience in diagnosing and treating blood disorders. Dedicated interdisciplinary groups, combining hematology with infectious disease imaging and pulmonary medicine, further elevate the hospital’s diagnostic and therapeutic capabilities, resulting in improved outcomes for patients with complex hematological conditions. In addition to routine laboratory evaluations, Beijing GoBroad Boren Hospital offers specialized diagnostic services, including cytological analysis, flow cytometry, chromosomal studies, and advanced techniques such as fluorescence in situ hybridization (FISH). The hospital also provides comprehensive genetic testing, including assessments for cancer-related genes, hereditary and susceptibility markers, pharmacogenetic profiling, and pathogen identification, alongside dedicated virology and pharmacology laboratories. The hospital’s clinicians are leaders in comprehensive diagnostics and tailored treatment approaches for blood diseases, utilizing a full spectrum of therapies, from chemotherapy and radiotherapy to immunotherapy, targeted agents, and demethylating drugs. Renowned for excellence in cellular immunotherapy, the center has achieved significant breakthroughs in CAR-T therapy for difficult-to-treat and relapsed leukemia, as well as for lymphomas and myeloma in both children and adults. Their innovative research is frequently showcased at major global hematology conferences and has garnered international recognition from the scientific and medical community. The hematopoietic stem cell transplantation program boasts extensive experience, offering transplants to patients ranging from infants as young as 1 month to adults up to 72 years old. With thousands of successful procedures performed, their outcomes align with top international standards. The transplant specialists excel in determining optimal timing and indications, selecting from various transplant modalities, including matched sibling, unrelated, haploidentical, cord blood, syngeneic, and autologous options, and customizing preparative regimens for each patient. The team is highly proficient in managing complications, providing post-transplant immunotherapies targeting leukemia, viral, and fungal threats, and bridging transplants with CAR-T therapy. They are recognized for tackling complex haploidentical and salvage transplants for resistant or relapsed cases, and are at the forefront of advances in thalassemia, bone marrow transplantation, and CAR-T cellular immunotherapy for diseases like multiple myeloma and acute lymphoblastic leukemia.